Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Publication date: Nov 26, 2019

The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).

Concepts Keywords
Adaptive Immune System Hypersensitivity
Antibody MS
Antigen Pheresis
Azathioprine Immunotherapies
Bioavailability Lymphoid irradiation
Bladder Vaccination
Blood Contraception
Blood Counts Medical specialties
Bone Marrow Drugs
Bowel Medicine
Brain Purines
Breast Feeding Immunosuppressants
Central Nervous System Cladribine
Cladribine Organochlorides
Clinical Examination Monoclonal antibodies
Condom Natalizumab
Contraception Multiple sclerosis
Contraindication Progressive multifocal leukoencephalopathy
Corticosteroid Azathioprine
Corticosteroids Antibodies
Cyclophosphamide MRI
Cyclosporine
Cytokine
Differential
Gadolinium
Hepatitis
HIPPA
HIV Positive
Hormonal Contraceptive
Hormonal Contraceptives
Hospital
Hypersensitivity
IgG
IgM
Immunocompromised
Immunology
Immunosuppressive
Immunotherapies
Informed Consent
Infusion
Integrin
IUD
IVIG
Lactating
Leukocytes
Lymphocyte
Lymphocytes
Lymphoid
Magnitude
Malignancy
Methotrexate
Mitoxantrone
Monoclonal Antibodies
MRI
Multiple Sclerosis
Myelin Sheath
Myeloid
Myelosuppressive
Natalizumab
Neutrophil
Oligodendrocytes
Opportunistic Infection
Pharmacological
Pheresis
Platelet
PML
Pregnancy
Progressive
Protocol
Remission
Renal
Renal Insufficiency
Secondary Lymphoid Organs
Spermicide
Spinal Cord
Tablets
Texas
Tuberculosis
United States
Uterine
Vaccination
Vaccine
Washout
X Ray

Semantics

Type Source Name
drug DRUGBANK Cladribine
drug DRUGBANK Natalizumab
disease MESH relapsing-remitting multiple sclerosis
disease MESH secondary progressive multiple sclerosis
disease MESH Diagnosis
disease MESH relapses
drug DRUGBANK Methylergometrine
disease MESH Syndrome
disease MESH hypersensitivity
drug DRUGBANK Mitoxantrone
drug DRUGBANK Azathioprine
drug DRUGBANK Methotrexate
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Immune Globulin Human
disease MESH hepatitis C
pathway KEGG Hepatitis C
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH latent tuberculosis
drug DRUGBANK Gold
drug DRUGBANK Ciclosporin
disease MESH malignancy
disease MESH fructose intolerance
drug DRUGBANK Gadolinium
disease MESH contraindication
disease MESH renal
disease MESH renal insufficiency
disease MESH Multiple Sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *